logo_finallogo_finallogo_finallogo_final
  • Home
  • Research
  • Our Services
  • Education
  • Book an Appointment
  • Contact Us
  • Review Us
  • Education
  • Book an Appointment
  • Contact Us
  • Review Us
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
October 7, 2019
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab
October 7, 2019

Furthering his studies in studying anti-VEGF injections (used as the primary treatment in Age-Related Macular Degeneration, Diabetic Retinal Diseases, and Retinal Vein Occlusions) he also led a study of the first study comparing practice patterns and need for anti-VEGF injections globally.

Purpose

A comparison of anti–vascular endothelial growth factor (anti-VEGF) medication use across multiple countries.

Clinical Relevance

Anti-VEGF medication use is now considered first-line treatment for numerous retinal diseases globally. Exploring medication choices, costs within each healthcare system, policy challenges, emerging treatments, and patient access all provide insight into a newly recognized and major public health issue.

Methods

All data presented in this review are available through the published English literature in PubMed, non–peer-reviewed trade publications, and reported surveys. The following search terms were used: anti-VEGF OR bevacizumab OR ranibizumab OR aflibercept OR pegaptanib OR conbercept AND trends OR survey OR cost OR patterns OR preference. Countries with large populations and available data included the United States, United Kingdom, China, India, Korea, Singapore, and Australia. Population and economic statistics were obtained from published reports from the World Bank, World Health Organization, and Commonwealth Fund.

Results

Anti-VEGF medication use and costs are significant aspects of patient and healthcare system expenditures in each nation and may have an especially large potential economic burden in India and China. Bevacizumab use comprises the majority of anti-VEGF medication use in the United States and Singapore, although aflibercept use is growing rapidly. Paradoxically, data demonstrate that there is a significant trend in medication choice toward ranibizumab and aflibercept among practice settings outside of the United States, such as the United Kingdom, China, South Korea, and Australia. The price of anti-VEGF medications ranged from US $30 (ziv-aflibercept) to US $1950 (ranibizumab and aflibercept). Ranibizumab’s price ranged from US $240 in India to US $1950 in the United States. Conbercept in China costs approximately US $1150 per dose.

Conclusions

Outside of the United States, many nations are using a majority of more expensive anti-VEGF medications, which may lead to increased costs and decreased access. Increasing the availability of safely compounded anti-VEGF medications will likely improve access, create patient/provider choice, and decrease relative healthcare costs for the growing burden of retinal diseases globally.

Related posts

November 19, 2019

Dr Parikh Presenting at Cornell Medical School


Read more
October 21, 2019

Dr. Parikh Lecturing at the 2019 American Academy of Ophthalmology meeting, the largest meeting of ophthalmologists in the US


Read more
October 14, 2019

Dr. Parikh leading a team of colleagues from Yale School of Medicine and Harvard/Mass Eye and Ear/Mass General examining screening rates of Diabetic Retinopathy published in Ophthalmology


Read more

Contact Us

  • 67 E 78th Street (and Park Ave) Unit 1c New York NY 10075
  • (212)-744-2513
  • (212)-744-4816
  • info@manhattanretinaeye.com

Location Map

Recent Posts

  • Injections

    Injections into the eye sound …
  • Eye Imaging

    Eye Imaging refers to digital …
  • Laser Surgery

      Laser eye surgeries are …
© 2019 Manhattan Retina and Eye. All Rights Reserved